Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...
12h
Zacks Investment Research on MSNSarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results